Johnson takes chair at Dendreon
This article was originally published in Scrip
John Johnson, who became Dendreon's CEO in February this year (scripintelligence.com, 1 February 2012), has assumed the title of chair as well, ousting Dr Mitchell Gold as planned. Dr Gold will continue to serve as a director.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.